
CLAIMS

What is claimed is:

1. Use of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein the medicament is to be orally administered for at least 53-260 weeks.

2. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein hemoglobin levels are increased to 10.0 – 13.0 g/dL from a baseline hemoglobin level in the subject.

3. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein hemoglobin levels are maintained or controlled at 10.0 – 13.0 g/dL.

4. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 53 weeks.

5. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 64 weeks.

6. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 76 weeks.

7. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 88 weeks.

8. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 104 weeks.

9. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 116 weeks.

10. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-2, wherein the medicament is to be administered to the subject for at least about 128 weeks.

11. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 140 weeks.

12. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 156 weeks.

13. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 168 weeks.

14. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 180 weeks.

15. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 192 weeks.

16. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 208 weeks.

17. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 260 weeks.

18. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-17, wherein the subject has non-dialysis dependent chronic kidney disease (NDD-CKD).

19. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-17, wherein the subject has dialysis-dependent chronic kidney disease (DD-CKD).

20. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-19, wherein the subject has been previously treated with an erythropoiesis stimulating agent (ESA).

21. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 20, wherein the subject has been previously treated with an erythropoiesis stimulating agent (ESA) within about eight weeks prior to or during a screening period before administering the medicament.

22. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 20, wherein the subject has been previously treated with an erythropoiesis stimulating agent (ESA) within about six weeks prior to or during a screening period before administering the medicament.

23. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 21 or 22, wherein the screening period is up to about eight weeks.

24. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 21 or 22, wherein the screening period is up to about 6 weeks.

25. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 21 or 22, wherein the screening period is up to about 4 weeks.

26. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 20-25, wherein the erythropoiesis stimulating agent is epoetin, darbepoetin alfa (DA), or methoxy polyethylene glycol-epoetin beta (epoetin beta pegol).

27. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the epoetin is epoetin alfa, epoetin beta, epoetin gamma, epoetin kappa, or a combination thereof.

28. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 27, wherein the subject has been previously treated with epoetin alfa in an amount of 10 U/kg to 500 U/kg 3 times weekly.

29. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with epoetin beta pegol in a dosage amount of 0.6 mcg/kg to 1.20 mcg/kg once every two weeks.

30. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with epoetin beta pegol in a dosage amount of 0.6 mcg/kg to 1.20 mcg/kg once monthly.

31. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with epoetin at a dose of ≥ 4500 IU weekly.

32. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with epoetin at a dose of about <4500 IU.

33. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of 0.45 mcg/kg to 0.75 mcg/kg once every four weeks.

34. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of 0.45 mcg/kg to 0.75 mcg/kg once every two weeks.

35. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of 0.45 mcg/kg to 0.75 mcg/kg once a week.

36. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with darbepoetin alfa in a dosage amount of ≥ 15 µg weekly.

37. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 26, wherein the subject has been previously treated with darbepoetin alfa in a dosage amount of about < 15 µg weekly.

38. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-37, wherein the medicament is to be administered at a dosage comprising 150-600 mg.

39. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-38, wherein the medicament is to be administered at a dosage comprising about 150 mg.

40. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-38, wherein the medicament is to be administered at a dosage comprising about 300 mg.

41. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-38, wherein the medicament is to be administered at a dosage comprising about 450 mg.

42. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-38, wherein the medicament is to be administered at a dosage comprising about 600 mg.

43. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-42, wherein the medicament is to be administered once daily.

44. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-42, wherein the medicament is to be administered once a week.

45. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-42, wherein the medicament is to be administered three times a week.

46. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the subject has a hemoglobin level of 8.0 g/dL to 13.0 g/dL.

47. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the subject has a hemoglobin level of ≥13.0 g/dL.

48. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-47, wherein the subject has a baseline hemoglobin level of about <10 g/dL.

49. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-45 and 48, wherein the hemoglobin levels are increased to 10.0-11.0 g/dL.

50. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-45 and 48, wherein the hemoglobin levels are increased to 11.0-13.0 g/dL.

51. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 38-42, wherein the medicament is to be administered comprising adjusting the dosage by about 150 mg if the subject's hemoglobin (Hb) level is < 10.0 g/dL or > 11.5 g/dL.

52. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 51, wherein the medicament is to be administered further comprising increasing the dosage, and the subject's hemoglobin (Hb) level is < 10.0 g/dL.

53. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 51, wherein the medicament is to be administered further decreasing the dosage.

54. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 38-42, and 51, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 2 weeks.

55. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 38-42, and 51-53, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 4 weeks.

56. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 38-42, and 51-53, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 6 weeks.

57. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 38-42, wherein the medicament is to be administered further comprising decreasing the dose no more than once in at least every 2 weeks.

58. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-45, and 48, wherein the hemoglobin levels are maintained or controlled at 10.0 – 12.0 g/dL.

59. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-45, and 48, wherein the hemoglobin levels are maintained or controlled at 11.0 – 13.0 g/dL.

60. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-59, wherein the patient has a serum ferritin level of ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%.

61. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-60, wherein the patient has a decrease in serum ferritin level relative to a baseline level.

62. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-61, wherein the patient is ≥ 18 years old.